The DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index.
KRAS Alleles: The Devil Is in the Detail
Open accessAbstract
KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is, as yet, not directly druggable, efforts to target KRAS mutant cancers focus on identifying vulnerabilities in downstream signaling pathways or in stress response pathways that are permissive for strong oncogenic signaling. One aspect of KRAS biology that is not well appreciated is the potential biological differences between the many distinct KRAS activating mutations. This review draws upon insights from both clinical and experimental studies to explore similarities and differences among KRAS alleles. Historical and emerging evidence supports the notion that the specific biology related to each allele might be exploitable for allele-specific therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“G12D and G12V mutations are the most common in PDAC, followed by G12R.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS G12R, G13D, Q61H, Q61L, and A146T mutations have increased intrinsic exchange relative to wildtype, but G12C and G12V do not display large changes [4,29,30,31,32].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“G12C and G12V mutations are predominant in lung adenocarcinomas with smoking-associated mutational signatures [30,32].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Specific KRAS mutations show characteristic patterns of tissue preference (Figure 1b,c).”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“KRAS A146 mutations are primarily found in colorectal cancer and are rarely reported in other types.”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [32]
In the citing paper
“Although epidemiological studies connect specific alleles to clinical outcomes, the mechanisms underlying the distinct clinical characteristics of mutant KRAS alleles are unclear.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“associations have been uncovered between the specific KRAS mutation status and therapeutic responses and clinical outcomes of cancer patients3,6”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“indicating possible differences in signaling behavior of the mutant proteins that exploit the environment of the specific cellular context3,4”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“the activating alleles found in KRAS vary substantially across cancers”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [3]
In the citing paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [6]
In the citing paper
“Notably, mutations in codons 117 (K117N/R) and 146 (A146T/V) are seen exclusively in colon cancers [51].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [51]
In the citing paper
“G12D and G12V are the most common in PDAC, which also shows enrichment for the G12R mutation that is rarely found in CRC lung and lung cancer (16).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“As the sequences of whole cancer genomes become available, we are getting an unparalleled look at frequency and variability of KRAS alleles across the spectrum of primary and metastatic cancers (Figure 1A,B) [3].”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Flagged first, then by citations
3 of the 85 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 376
The role of the 12(S)-HETE/GPR31/12-HETER axis in cancer and ischemia–reperfusion injury
Napolitano, M. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180635 · Cited by 10
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Damianou, A., Liang, Z., Lassen, F. H., Vendrell, I., Vere, G., Hester, S., Charles, P. D., Pinto-Fernández, A., Santos, A., Fischer, R., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302245 · Cited by 11
Su, A., Liu, Y., Sun, W., Liang, C., Xu, W., Rodger, A., Piper, J. A., Wang, Y., & Xu, S. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c01925 · Cited by 9
Yang, C., Li, H.-X., Gan, H., Shuai, X., Dong, C., Wang, W. J., Lin, D., & Zhong, B. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.01.015 · Cited by 9
Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer
Marin, A. M., Sanchuki, H. B. S., Namur, G. N., Uno, M., Zanette, D. L., & Aoki, M. N. (2023) · Biomedicines · doi:10.3390/biomedicines11041069 · Cited by 9
Prospects and challenges of CRISPR /Cas9 gene‐editing technology in cancer research
Li, N., Xi, J., Yin, Z., Chen, M., Zou, Q., Zhou, X., & Tang, C. (2023) · Clinical Genetics · doi:10.1111/cge.14424 · Cited by 11
Liou, G., Byrd, C. J., Störz, P., & Messex, J. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094726 · Cited by 8
Oncogenic KRAS hotspot mutations are rare in IDH‐mutant gliomas
Schittenhelm, J., Krischker, N., Gepfner‐Tuma, I., Behling, F., Noell, S., Eckert, F., Biskup, S., & Tabatabai, G. (2019) · Brain Pathology · doi:10.1111/bpa.12709 · Cited by 9
Shao, Y., Ma, L., Zhang, T., Xu, T., Ye, Y., & Liu, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828162217 · Cited by 11
K-ras peptide mimotope induces a humoral immune response against G12V K-ras antigen in BALB/c mice
Hoo, W. P. Y., Siak, P. Y., Alias, N. A. R., Wong, J. J., Tan, E. W., Song, A. A., Rahim, R. A., & In, L. L. A. (2020) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2020.028.3.03 · Cited by 9
Wong, G. Y. M., Bhimani, N., Mol, B. M., Diakos, C. I., de Reuver, P., Molloy, M. P., & Hugh, T. J. (2022) · HPB · doi:10.1016/j.hpb.2022.01.003 · Cited by 9
Molecular targets of primary cilia defects in cancer (Review)
Yin, F., Wei, Z., Chen, F., Xin, C., & Chen, Q. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5388 · Cited by 8
Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum
Grabski, I. N., Heymach, J. V., Kehl, K. L., Kopetz, S., Lau, K. S., Riely, G. J., Schrag, D., Yaeger, R. D., Irizarry, R. A., & Haigis, K. M. (2023) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-0262 · Cited by 8
Self-citationGTP hydrolysis is modulated by Arg34 in the RASopathy‐associated KRASP34R
Bera, A. K., Lu, J., Lu, C., Li, L., Gondi, S. R., Yan, W., Nelson, A., Zhang, G., & Westover, K. D. (2020) · Birth Defects Research · doi:10.1002/bdr2.1647 · Cited by 8
Mitochondria–ER crosstalk via MAMS: Bridging cellular homeostasis and cancer progression
Roy, R., Adhikary, A., De, R., & Ghosh, S. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02252-4 · Cited by 7
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
Jung, Y. H., Choi, Y., Seo, H., Seo, M., & Kim, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.019 · Cited by 7
Mateoiu, C., Palicelli, A., Maloberti, T., de Biase, D., Leo, A. D., Lindh, M., Bohlin, K. S., & Stolnicu, S. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155181 · Cited by 7
New insights into testicular granulosa cell tumors (Review)
Fang, X. D., & Li, Q. (2020) · Oncology Letters · doi:10.3892/ol.2020.12156 · Cited by 7
Jun, E., Koo, B., Kim, E. J., Hwang, D. W., Lee, J. H., Song, K. B., Lee, W., Park, Y., Hong, S., Shin, Y. M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111599 · Cited by 7
Kohno, T., & Kojima, T. (2022) · Cancers · doi:10.3390/cancers14205056 · Cited by 7
YB-1 activating cascades as potential targets in KRAS-mutated tumors
Khozooei, S., Veerappan, S., & Toulany, M. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02092-8 · Cited by 6
Adeniji, E. A., Olotu, F. A., & Soliman, M. E. S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180718110231 · Cited by 7
Ma, Y., Xu, J., Huang, P., Bai, X., & Hanqing, G. (2018) · IUBMB Life · doi:10.1002/iub.1945 · Cited by 7
Cholangiocarcinoma Therapeutics: An Update
Nguyen, M. L. T., Toàn, N. L., Bożko, M., Bùi, K. C., & Bozko, P. M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210204152028 · Cited by 8
Zhang, H., Yuan, L., Liu, L., Yan, C., Cheng, J., Fu, Q., Tong, Z., Jiang, W., Zheng, Y., Zhao, P., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06909-y · Cited by 7
Chronic rhinosinusitis with nasal polyps does not harbor KRAS, BRAF, and EGFR mutations
Vieira, T. D. S., Guimarães, L. M., Diniz, M. G., Gomes‐Fernandes, B., Anselmo‐Lima, W. T., Tamashiro, E., Bastos‐Rodrigues, L., Marco, L. A. D., Gomez, R. S., Valera, F. C. P., et al. (2022) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13356 · Cited by 6
Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel
Gregori, A., Bergonzini, C., Capula, M., de Mercado, R. R., Danen, E. H. J., Giovannetti, E., & Schmidt, T. (2024) · Cancers · doi:10.3390/cancers16223863 · Cited by 6
The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
Rackley, B. B., Seong, C.-S., Kiely, E. J., Parker, R. E., Rupji, M., Dwivedi, B., Heddleston, J. M., Giang, W., Anthony, N. R., Chew, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01663-8 · Cited by 6
Ras Isoforms from Lab Benches to Lives—What Are We Missing and How Far Are We?
Nair, A., Kubatzky, K. F., & Saha, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126508 · Cited by 7
KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer
Althaiban, A., Thyagarajan‐Sahu, A., & Sahu, R. P. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221226095931 · Cited by 6
bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsPreprint
Lim, S., Khoo, R., Juang, Y.-C. A., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174565 · Cited by 6
Structural Dynamics of Rho GTPases
Lin, Y., & Zheng, Y. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168919 · Cited by 6
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5
Xiao, B., Zhang, Y., Lu, Z., Chen, W., An, Y., Zu, G., Xu, X., Wu, D., Yang, H., Qin, Y., et al. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022111 · Cited by 5
Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
Ren, B., 高卓维, Zheng, K., Yang, Y., Su, P., Luo, Q., Feng, J., Zhentao, L., Geng, Y., Ju, Y., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11942 · Cited by 6
Role of silent mutations in KRAS-mutant tumors
Lu, J. G., Zhou, C., Pan, F., Liu, H., Jiang, H., Zhong, H., & Han, B. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003405 · Cited by 6
Jobu, Y., Nishigawa, M., Furihata, K., Furihata, M., Uchida, K., & Taniuchi, K. (2025) · Human Cell · doi:10.1007/s13577-024-01165-9 · Cited by 5
Song, J., Wang, B., Zou, M., Zhou, H., Ding, Y., Ren, W., Fang, L., & Zhang, J. (2025) · Biology · doi:10.3390/biology14050477 · Cited by 5
Mechanisms and Markers of Clinical Radioresistance
Binkley, M. S., Diehn, M., Eke, I., & Willers, H. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_4 · Cited by 6
Kyriakopoulos, G. C., Katopodi, V., Skeparnias, I., Kaliatsi, E. G., Grafanaki, K., & Stathopoulos, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042222 · Cited by 5
Drugging the undruggable: a computational chemist's view of KRAS G12C
Bodnarchuk, M. S., Cassar, D. J., Kettle, J. G., Robb, G. R., & Ward, R. A. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00055a · Cited by 5
Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
Carvalho, P. D., Martins, F., Carvalho, J., Oliveira, M. J., & Velho, S. (2022) · Cells · doi:10.3390/cells11131988 · Cited by 7
Izumi, K., Ganetzky, R. D., Wertheim, G. B. W., Skraban, C. M., Bedoukian, E. C., Wilkens, A., Fincher, C. T., Thomas, N. H., Ginsberg, J. P., Rheingold, S. R., et al. (2023) · Molecular Syndromology · doi:10.1159/000530197 · Cited by 5
Etiopathogenesis and Treatment of Colorectal Cancer
Bocchi, M., Fernandes, E. V., Pereira, N. D. S., & Amarante, M. K. (2025) · Immuno · doi:10.3390/immuno5030031 · Cited by 5
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 5
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
Shiller, M., Johnson, M. L., Auber, R., & Patel, S. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1459737 · Cited by 8
Adorisio, R., Ciardiello, D., Rappa, A., Gervaso, L., Pelizzari, G., Marinucci, L., Fusco, N., Zampino, M. G., Fazio, N., Venetis, K., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.11.007 · Cited by 5
Hu, X., Zhang, R., Yao, J., Mu, B., & Zhao, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12891 · Cited by 4
Guimarães, L. M., Vieira, T. D. S., Marco, L. A. D., Thompson, L. D. �., & Gomes, C. C. (2022) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13394 · Cited by 4
Landscape of somatic mutated genes and inherited susceptibility genes in gynecological cancer
Watanabe, T., Soeda, S., Okoshi, C., Fukuda, T., Yasuda, S., & Fujimori, K. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15766 · Cited by 4
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
Jia, M., Feng, S., Cao, F., Deng, J., Li, W., Zhou, W.-Y., Liu, X., & Bai, W. (2022) · Cancers · doi:10.3390/cancers14205073 · Cited by 4
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background
Budagyan, K., & Chernoff, J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_20 · Cited by 4
In vivo KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitorPreprint
Imanishi, S., Huang, L., Itakura, S., Ishizaka, M., Iwasaki, Y., Yamaguchi, T., & Miyamoto‐Sato, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.23.441075 · Cited by 5
Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Grimont, A., Falvo, D. J., Sisso, W. J., dos Santos, F., Chan, C. W., Zumbo, P., Fall, W. B., Ferrick, K. R., Pan, G., Cleveland, M., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.06.016 · Cited by 4
Li, D., Xie, Q., Yang, M., Sun, K., Jiang, S., Yu, S., Liu, L., Yu, B., Li, L., Zhang, Y., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00300 · Cited by 3
Trametinib Inhibits Lymphatic Vessel Invasion of Bone in a Mouse Model of Gorham-Stout Disease
McCarter, A., & Dellinger, M. T. (2023) · Journal of Vascular Anomalies · doi:10.1097/jova.0000000000000070 · Cited by 3
Zhang, B., Chen, X., Song, H., Gao, X. J., Ma, S., Ji, H., Qu, H., Xia, S., & Shang, D. (2024) · Journal of Cancer · doi:10.7150/jca.100891 · Cited by 4
Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications
Khattab, S., Berisha, A., Baran, N., & Piccaluga, P. P. (2025) · Biomedicines · doi:10.3390/biomedicines13010202 · Cited by 4
Martins, F., Machado, A. L., Carvalho, J., Almeida, C. R., Beck, H. C., Carvalho, A. S., Backman, V., Matthiesen, R., & Velho, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-94549-2 · Cited by 3
Brak, H. H., & Thielman, N. R. J. (2025) · Advances in Biological Regulation · doi:10.1016/j.jbior.2025.101097 · Cited by 3
KRAS oncogenic mutations in benign tumors: adenomatoid odontogenic tumor as a model
Coura, B. P., Guimarães, L. M., Gomez, R. S., & Gomes, C. C. (2025) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2025.108552 · Cited by 3
Exploring the genetic alterations of Gorham-Stout disease
Pagliarosi, O., Pepe, J., Fattore, A. D., & Rossi, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1654497 · Cited by 3
KRAS: Structure, function, and development of anticancer drugs
Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3
Liu, D., Chen, T., Yu, K., Li, J., Wang, S., Ma, X., Zhu, Q., Ning, Y., & Wang, Y. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03367-8 · Cited by 3
Yang, W., Ge, J., Yuan, M., Li, J., Pan, L., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001428 · Cited by 3
Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer
Schulz, B., Leitner, E., Schreiber, T., Lindner, T., Schwarz, R., Aboutara, N., Ma, Y., Escobar, H. M., Palme, R., Hinz, B., et al. (2024) · Cancers · doi:10.3390/cancers16101901 · Cited by 3
The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?
Barbosa, I. D. S., Heming, C. P., Moura‐Neto, V., & Aran, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094104 · Cited by 3
Li, Y., Monzó, M., Moreno, I., Martínez-Ródenas, F., Hernandez, R., Castellano, J. J., Canals, J., Han, B., Muñoz, C., & Navarro, A. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03538-6 · Cited by 3
The Endeavours in RAS Inhibition - the Past, Present, and Future
Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 3
Mutant Allele Imbalance in Cancer
Bielski, C. M., & Taylor, B. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051320-124252 · Cited by 3
Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation
Aiderus, A., Contreras-Sandoval, A. M., Meshey, A. L., Newberg, J. Y., Ward, J. M., Swing, D. A., Copeland, N. G., Jenkins, N. A., Mann, K. M., & Mann, M. B. (2021) · Cancers · doi:10.3390/cancers13020225 · Cited by 3
A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancerPreprint
Kaushik, S., Haderk, F., Zhao, X., Hu, H., Shah, K. N., Jang, G. Μ., Olivas, V. R., Nanjo, S., Jascur, J., Masto, V. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.185173 · Cited by 3
Damianou, A., Liang, Z., Lassen, F. H., Vere, G., Hester, S., Charles, P. D., Pinto-Fernández, A., Santos-Delgado, A., Fischer, R., & Kessler, B. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.23.469679 · Cited by 3
Tian, C., LI, X., & Ge, C. (2021) · Research Square · doi:10.21203/rs.3.rs-361646/v1 · Cited by 3
Islam, M. S., Ranjit, E., Aktar, S., Moetamedirad, N., Lu, C., Shiddiky, M. J. A., Gopalan, V., & Lam, A. K.-Y. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167982 · Cited by 2
Xie, W., Liu, H., Shi, Y., Zhang, B., Wang, R., Wang, S., & Liang, B. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1617930 · Cited by 2
Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches
Karki, R., Chen, R., & Pan, S. (2025) · Current Oncology · doi:10.3390/curroncol32110614 · Cited by 3
FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer
Ber, S., Yang, M. H., Sciacovelli, M., Samarajiwa, S., Patel, K., Nikitopoulou, E., Howitt, A., Cook, S. J., Venkitaraman, A. R., Frezza, C., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00641-z · Cited by 2
Seamon, K. J., Zhuang, Y., Yang, Y. C., Chakraborty, S., Cregg, J., Tomlinson, A. C. A., Gould, A., Ahler, E., Maldonato, B. J., Spradlin, J. N., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0886 · Cited by 3
Choi, S. Y., Kim, H. W., Jeon, S. H., Kim, B. N., Kang, N., Yeo, C. D., Park, C. K., Kim, Y. K., LEE, Y. H., Lee, K. Y., et al. (2019) · In Vivo · doi:10.21873/invivo.11563 · Cited by 2
Advances in the study of corticoid and melatonin in circadian rhythm disorders of oncology patients
Liang, J., Luo, L., & Wang, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5675 · Cited by 2
Pineocytoma in a child with Pallister–Killian syndrome: a case report and review of the literature
Martino, L. D., Russo, C., Bifano, D., Quaglietta, L., Spennato, P., & Cinalli, G. (2024) · Child s Nervous System · doi:10.1007/s00381-024-06426-4 · Cited by 1
Interaction between microRNA and KRAS in Glioblastoma
Beylerli, O., Мусаев, Э. Р., Soto, G. R., Castillo-Rangel, C., Ramírez, M. D. J. E., & Ilyasova, T. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673343892241207034138 · Cited by 1
Hrčkulák, D., Onhajzer, J., Krausová, M., Šťastná, M., Křı́ž, V., Janečková, L., & Kořínek, V. (2025) · Transgenic Research · doi:10.1007/s11248-024-00429-2 · Cited by 1
Stereoselective synthesis of a KRAS G12C inhibitor with a quinoline-piperazine scaffold
Hu, Y., Zheng, J., Chen, Y.-J., Pu, W.-Y., Xu, Y., & Dong, L. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob02104e · Cited by 1
Adenomatoid odontogenic tumor molecular pathogenesis: focusing on KRAS oncogenic mutations
Gomes, I. P., & Gomes, C. C. (2025) · JORDI - Journal of Oral Diagnosis · doi:10.5327/2525-5711.301 · Cited by 1
Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells
Zhu, H., Yan, G., Ma, J., Zhang, B., Yan, Y., Zhu, L., Dong, R., Lin, N., & Tan, B. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04799-0 · Cited by 1
Rabbi, M. R., & Morshed, M. R. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100080 · Cited by 1
Differential effects of KRAS G-domain and hypervariable region mutants on cancer phenotypes
de Borja, J. A. D., Lin, K. D. J. H., Mirador, D. A. R., Ang, A. I. D., Chua, S. A. A., Sytangco, J. M. D., Sacdalan, D. L., & Garcia, R. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-22168-y · Cited by 1
BRAF p.Val600Glu Mutations Are Not Detected in Adenomatoid Odontogenic Tumors
Gonçalves, J. D. O., Coura, B. P., Bernardes, V. F., Marco, L. A. D., Martins, M. D., Pérez, D. E. D. C., Gomez, R. S., & Gomes, C. C. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100933 · Cited by 1
Ryu, S., Baig, M. H., Panwar, U., Dong, J.-J., Jo, Y. S., Kim, C. J., Nale, S. D., Park, J., Ha, J., Moon, B., et al. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111437 · Cited by 1
Fayad, C., Mussalo, L., Afonin, A., Lampinen, R., Hakkarainen, H., Hensel, A.-K., Yahfoufi, K., Behzadpour, D., Penttilä, E., Koivisto, A. M., et al. (2026) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2026.181661 · Cited by 1
Multiomics Research Strategies in Cancer: A Growing and Innovative Field
Du, Z., Liu, X., Lv, Z., Wang, B., Xia, Y., Al-duais, W. A. M., Yan, L., Zhang, F., & Li, Y. (2026) · MedComm · doi:10.1002/mco2.70644 · Cited by 1
The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium
Yang, M. H., Sheth, S., Shui, B., Grabski, I. N., Park, S. S., Galán‐Cobo, A., Irizarri, R., Heymach, J. V., Dow, L. E., & Haigis, K. M. (2026) · Oncogene · doi:10.1038/s41388-026-03771-3 · Cited by 1
Self-citationAlberti, M. O., Srivatsan, S. N., Shao, J., Fei, D. L., Zhu, M., Pastrana, C. C., Chavez, M., Tarnawsky, S. P., Grieb, S., Graubert, T. A., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02974-7 · Cited by 1
Zhao, Y., Wu, S., Yuan, X., & Zhao, C. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345660 · Cited by 1
Fan, H., Li, X., Song, H., Zhang, S., Tian, Z., Chen, Y., Zhou, J., Geng, S., Liu, H., Wang, Y., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124406 · Cited by 1
Metadata
- Authors
- Haigis, K. M.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Haigis, Kevin M.
- ORCID
- Haigis, Kevin M.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 3
- Issue
- 10
- Pages
- 686-697
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- PMC
- PMC5824632
- OpenAlex
- W2754809261
- Cited by
- 373
- References
- 85
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 41 · 2023: 42 · 2022: 60 · 2021: 54 · 2020: 52 · 2019: 39 · 2018: 11 · 2017: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Trends in cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH/NCI (CA178017, CA199252, CA195744)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS, KRAS mutation, oncogenic signaling, downstream signaling pathways, stress response pathways, cancer therapy resistance
- MeSH terms
- Alleles, Animals, Cell Transformation, Neoplastic, Genotype, Humans, Mutation, Neoplasms, Prognosis, Structure-Activity Relationship, Proto-Oncogene Proteins p21(ras), Genetic Predisposition to Disease, GTP Phosphohydrolases, Genetic Association Studies, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
